INT315796

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.32
First Reported 2009
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 3
Disease Relevance 5.00
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Tst) RNA binding (Tst) plasma membrane (Tst)
Anatomy Link Frequency
B-cell 4
Tst (Mus musculus)
Pain Link Frequency Relevance Heat
corticosteroid 9 16.84 Low Low
positron emission tomography 18 5.00 Very Low Very Low Very Low
imagery 9 5.00 Very Low Very Low Very Low
palliative 6 5.00 Very Low Very Low Very Low
Paracetamol 3 5.00 Very Low Very Low Very Low
vincristine 3 5.00 Very Low Very Low Very Low
Calcium channel 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Lymphatic System Cancer 204 100.00 Very High Very High Very High
Disease 75 100.00 Very High Very High Very High
Myelodysplastic Syndromes 42 98.28 Very High Very High Very High
Acute Myeloid Leukemia 39 98.12 Very High Very High Very High
Hypersensitivity 3 95.84 Very High Very High Very High
Anaerobic Bacterial Infections 3 93.36 High High
Measles 3 92.84 High High
Herpes Zoster 3 92.48 High High
Mumps 3 91.76 High High
Togavirus Infection 3 91.48 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
131I-TST is FDA approved for the treatment of relapsed or refractory low grade CD20+ B-cell NHL, including disease refractory to RTX, or transformed NHL.
Positive_regulation (transformed) of Gene_expression (transformed) of 131I-TST in B-cell associated with lymphatic system cancer and disease
1) Confidence 0.32 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 1.10 Pain Relevance 0
The annualized incidence of AML/MDS was 1.6%/year which is similar to that of patients treated with multiple chemotherapy regimens.29 In a study of 76 patients treated with upfront 131I-TST monotherapy for follicular NHL, no patients developed MDS/AML with a median follow-up of 7.93 years.30 Distinguishing the attributable risk of MDS/AML to chemotherapy or 131I-TST is difficult, although it appears that 131I-TST does not significantly increase the risk of leukemia.29

131I-TST in relapsed B-cell NHL

Positive_regulation (upfront) of Gene_expression (monotherapy) of 131I-TST in B-cell associated with leukemia, lymphatic system cancer, myelodysplastic syndromes and acute myeloid leukemia
2) Confidence 0.32 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 2.09 Pain Relevance 0
Few patients lost acquired humoral immunity suggesting that routine revaccination of patients after 131I-TST is unnecessary.28
Positive_regulation (after) of Gene_expression (unnecessary.28) of 131I-TST
3) Confidence 0.32 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 1.81 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox